Cancer – Patient Worthy

ImmunityBio Reports Encouraging Evidence That ANKTIVA Enhances Immune Recovery in NSCLC When Paired With Checkpoint Inhibitors

Post author:Austin Newman
Post published:January 22, 2026
Post category:non-small cell lung cancer

As reported on Business Wire, ImmunityBio has released new clinical findings suggesting that its interleukin‑15 superagonist, ANKTIVA® (nogapendekin alfa inbakicept), may help restore immune function and improve survival outcomes in…

AstraZeneca’s LATIFY Trial Misses Primary Endpoint in Previously Treated Advanced NSCLC

Post author:Austin Newman
Post published:January 20, 2026
Post category:non-small cell lung cancer

As reported on PharmaBiz, AstraZeneca’s phase III LATIFY trial has fallen short of its primary objective, with the combination of the ATR inhibitor ceralasertib and the PD‑L1 inhibitor Imfinzi (durvalumab)…

“The Aftermath: Nobody Told Me This Part Would Hurt Too: – Megan’s Fight Against Non-Hodgkin’s Lymphoma

Post author:PW Collaborator
Post published:January 15, 2026
Post category:Non-Hodgkin's Lymphoma

Editor's Note: Patient Worthy is proud to share this story from our friends at Elephants & Tea. To see the story in its original format, please click here. “Well, good…

A Conversation About Survivorship

Post author:Patient Worthy Contributor
Post published:January 13, 2026
Post category:Lymphoma

Editor's Note: Patient Worthy is proud to share this article, originally written by Katie Tat, from our friends at Elephants & Tea. To see the article in its original format,…

Risk-Based Breast Cancer Screening Shows Promise in Major U.S. Study

Post author:Austin Newman
Post published:January 8, 2026
Post category:Breast Cancer

As reported on Science Daily, a groundbreaking study suggests that customizing breast cancer screening based on individual risk factors may outperform the traditional one-size-fits-all approach of annual mammograms. The research,…

FDA Grants Full Approval to Rucaparib for BRCA-Mutated mCRPC

Post author:Austin Newman
Post published:January 7, 2026
Post category:Rare Disease

In a recent statement, the U.S. Food and Drug Administration (FDA) has authorized regular approval to rucaparib (Rubraca) for adults with metastatic castration-resistant prostate cancer (mCRPC) harboring deleterious BRCA mutations—either…

Incyte Reports Positive Phase III Results for Tafasitamab in First-Line DLBCL Treatment

Post author:Austin Newman
Post published:January 7, 2026
Post category:Diffuse Large B-cell Lymphoma

Incyte has announced encouraging top-line findings from its pivotal Phase III frontMIND trial, evaluating tafasitamab (marketed as Monjuvi/Minjuvi) in combination with lenalidomide and the standard R-CHOP regimen for newly diagnosed…

FDA Approves J&J’s Akeega for BRCA2-Mutated mCSPC, Marking a New Era in Precision Prostate Cancer Care

Post author:Austin Newman
Post published:January 5, 2026
Post category:Prostate Cancer

As reported on FiercePharma, Johnson & Johnson has secured a significant milestone in prostate cancer treatment with the FDA’s approval of Akeega for patients with BRCA2-mutated metastatic castration-sensitive prostate cancer…

Raspberry Sorbet Swirls in the Sky

Post author:Patient Worthy Contributor
Post published:December 25, 2025
Post category:Colorectal cancer

Editor's Note: This poem, originally written by Spence Shishido, was shared with Patient Worthy by our friends at Elephants & Tea. To see the poem in its original format, please…

Early Use of Tecvayli Shows Potential for Functional Cure in Multiple Myeloma

Post author:Austin Newman
Post published:December 17, 2025
Post category:Multiple Myeloma

As reported on BioPharmaDive, new clinical trial data presented at the American Society of Hematology (ASH) annual meeting suggests that an early treatment regimen combining Tecvayli (Johnson & Johnson’s bispecific…

RFK’s Granddaughter, Tatiana Schlossberg, Reveals Diagnosis of Rare Blood Cancer

Post author:Austin Newman
Post published:December 11, 2025
Post category:Leukemia

As reported on NPR, Tatiana Schlossberg, journalist and granddaughter of former U.S. President John F. Kennedy, has disclosed that she is battling a rare and aggressive form of leukemia. In…

“The Part That Died”

Post author:PW Collaborator
Post published:December 10, 2025
Post category:Brain Cancer

Editor's Note: Patient Worthy is pleased to share this article from our friends at Elephants & Tea, originally written by Cecily Liu. To see the article in its original format,…

EMA Recommends Orphan Drug Status for BioInvent’s BI-1808 in Cutaneous T-Cell Lymphoma

Post author:Austin Newman
Post published:December 1, 2025
Post category:Cutaneous T-cell Lymphomas

As reported by PharmaBiz, the European Medicines Agency’s Committee for Orphan Medicinal Products (COMP) has issued a positive opinion supporting Orphan Drug Designation (ODD) for BioInvent’s BI-1808, an investigational anti-TNFR2…

New Liposomal Chemotherapy Agent Shows Breakthrough Potential Against Resistant Tumors

Post author:Austin Newman
Post published:November 24, 2025
Post category:Cancer

As reported on World Pharma News, a collaborative research team from the Medical University of Vienna, HUN-REN Research Centre for Natural Sciences, and Eötvös Loránd University has unveiled a promising…

Merck’s Welireg Shows Promise in Kidney Cancer Across Two Major Trials

Post author:Austin Newman
Post published:November 14, 2025
Post category:Renal cancer

Merck & Co. announced positive results from two Phase 3 studies of its kidney cancer drug Welireg, signaling potential expansion into earlier stages of disease. As reported on BioPharmaDive, in…

Danny Gereg Shares His Bladder Cancer Story

Post author:Austin Newman
Post published:November 12, 2025
Post category:Bladder cancer

We're honored to bring you this video, shared with us by Danny Gereg, that details some of his journey living with bladder cancer. Danny has stayed resilient and positive, finding…

How DNA Technology Can Guide Treatment in Muscle Invasive Bladder Cancer

Post author:Kathy Devanny
Post published:November 12, 2025
Post category:Bladder cancer

Author's Note: Patient Worthy began following Natera following their presentation at the American College of Medical Genetics conference many years ago. Natera has been known for its advances in prenatal…

An Overview on Bladder Cancer

Post author:Kathy Devanny
Post published:November 11, 2025
Post category:Bladder cancer

Genetics: a cosmic role of the dice that plays a role in so many medical conditions, including bladder cancer. Mutations in FGFR3, PIK3CA, KDM6A, and TP53 are commonly associated with bladder cancer, but…

New Epigenetic Editing Platform Enhances T Cell Therapies Without DNA Damage

Post author:Austin Newman
Post published:November 7, 2025
Post category:Cancer

A collaborative team from Arc Institute, Gladstone Institutes, and UCSF has unveiled a groundbreaking epigenetic editing platform that could revolutionize next-generation cell therapies. Published in Nature Biotechnology on October 21,…

The FDA has Issued a Complete Response Letter to Xspray Pharma Delaying Approvals Affecting ALL and CML

Post author:Rose Duesterwald
Post published:November 6, 2025
Post category:Cancer

Xspray Pharma, the developer of the drug dasatinib, was recently issued a Complete Response Letter (CRL) by the FDA while waiting for corrective actions, according to Cancer Network. Based on…

UChicago Medicine Launches Same-Day Breast Biopsy Program to Accelerate Cancer Diagnosis

Post author:Austin Newman
Post published:October 31, 2025
Post category:Breast Cancer

In a groundbreaking move to reduce the emotional toll and diagnostic delays associated with breast cancer detection, the University of Chicago Medicine has introduced BIOPSY NOW, a patient-centered initiative offering…

“A Letter to My 2020 Self”

Post author:Patient Worthy Contributor
Post published:October 30, 2025
Post category:Cancer

Editor's Note: Patient Worthy is proud to share this blog post by Carmen D., a cancer survivor and affectionately known as The Chemo Diva. To see the article in its…

Phase 2 GLEAM Trial of Zolbetuximab in Pancreatic Cancer Falls Short of Primary Endpoint

Post author:Austin Newman
Post published:October 28, 2025
Post category:Pancreatic Cancer

Astellas Pharma Inc. has announced that its Phase 2 GLEAM trial evaluating zolbetuximab in combination with gemcitabine plus nab-paclitaxel for metastatic pancreatic adenocarcinoma did not meet its primary endpoint of…

“My Own Worst Enemy” – Anna’s Experience with Hodgkin Lymphoma

Post author:PW Collaborator
Post published:October 26, 2025
Post category:Hodgkin Lymphoma

Editor's Note: Patient Worthy is honored to share this article from our friends at Elephants & Tea. To see the article in its original form, please click here. Dear Cancer,…

Navigating the Challenges of Biomarker Testing in Oncology: Innovations for Low-Yield Samples

Post author:Austin Newman
Post published:October 23, 2025
Post category:Cancer

Biomarker analysis plays a pivotal role in cancer care and research, guiding the development of targeted therapies and enabling personalized treatment plans. While next-generation sequencing (NGS) has revolutionized the ability…

ImmunityBio Reports Encouraging Evidence That ANKTIVA Enhances Immune Recovery in NSCLC When Paired With Checkpoint Inhibitors

AstraZeneca’s LATIFY Trial Misses Primary Endpoint in Previously Treated Advanced NSCLC

“The Aftermath: Nobody Told Me This Part Would Hurt Too: – Megan’s Fight Against Non-Hodgkin’s Lymphoma

A Conversation About Survivorship

Risk-Based Breast Cancer Screening Shows Promise in Major U.S. Study

FDA Grants Full Approval to Rucaparib for BRCA-Mutated mCRPC

Incyte Reports Positive Phase III Results for Tafasitamab in First-Line DLBCL Treatment

FDA Approves J&J’s Akeega for BRCA2-Mutated mCSPC, Marking a New Era in Precision Prostate Cancer Care

Raspberry Sorbet Swirls in the Sky

Early Use of Tecvayli Shows Potential for Functional Cure in Multiple Myeloma

RFK’s Granddaughter, Tatiana Schlossberg, Reveals Diagnosis of Rare Blood Cancer

“The Part That Died”

EMA Recommends Orphan Drug Status for BioInvent’s BI-1808 in Cutaneous T-Cell Lymphoma

New Liposomal Chemotherapy Agent Shows Breakthrough Potential Against Resistant Tumors

Merck’s Welireg Shows Promise in Kidney Cancer Across Two Major Trials

Danny Gereg Shares His Bladder Cancer Story

How DNA Technology Can Guide Treatment in Muscle Invasive Bladder Cancer

An Overview on Bladder Cancer

New Epigenetic Editing Platform Enhances T Cell Therapies Without DNA Damage

The FDA has Issued a Complete Response Letter to Xspray Pharma Delaying Approvals Affecting ALL and CML

UChicago Medicine Launches Same-Day Breast Biopsy Program to Accelerate Cancer Diagnosis

“A Letter to My 2020 Self”

Phase 2 GLEAM Trial of Zolbetuximab in Pancreatic Cancer Falls Short of Primary Endpoint

“My Own Worst Enemy” – Anna’s Experience with Hodgkin Lymphoma

Navigating the Challenges of Biomarker Testing in Oncology: Innovations for Low-Yield Samples

Let’s Work Together!

Keep Up to Date

Learn More